Nicole L. Votaw

Nicole L. Votaw

Auto-generated profile, based on publicly available information

Nicole L. Votaw

Department of Biomedical Engineering, Duke University, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Biomaterials
Verified
Journal Article
Closed access
NVNicole L. Votaw
Nicole L. Votaw
LCLauren Collier
Lauren Collier
ECElizabeth J. Curvino
Elizabeth J. Curvino
YWYaoying Wu
Yaoying Wu
CFChelsea N. Fries
Chelsea N. Fries
JCJoel H. Collier
Joel H. Collier

23 November 2022 in Science Advances
Verified
Journal Article
Open access
SKSean H. Kelly
Sean H. Kelly
NVNicole L. Votaw
Nicole L. Votaw
BCBenjamin J. Cossette
Benjamin J. Cossette
YWYaoying Wu
Yaoying Wu
SSShamitha Shetty
Shamitha Shetty
JCJoel H. Collier
Joel H. Collier
Urinary tract infections (UTIs) are a major public health problem affecting millions of individuals each year. Recurrent UTIs are managed by long-term antibiotic use, making the alarming rise of antibiotic resistance a substantial threat to future UTI treatment. Extended antibiotic regimens may also have adverse effects on the microbiome. Here, we report the use of a supramolecular vaccine to provide long-term protection against uropathogenic Escherichia coli , which cause 80% of uncomplicated UTIs. We designed mucus-penetrating peptide-polymer nanofibers to enable sublingual (under the tongue) vaccine delivery and elicit antibody responses systemically and in the urogenital tract. In a mouse model of UTI, we demonstrate equivalent efficacy to high-dose oral antibiotics but with significantly less perturbation of the gut microbiome. We also formulate our vaccine as a rapid-dissolving sublingual tablet that raises response in mice and rabbits. Our approach represents a promising alternative to antibiotics for the treatment and prevention of UTIs.

5 April 2021 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KHKelly M. Hainline
Kelly M. Hainline
LSLucas S. Shores
Lucas S. Shores
NVNicole L. Votaw
Nicole L. Votaw
ZBZachary J. Bernstein
Zachary J. Bernstein
SKSean H. Kelly
Sean H. Kelly
JCJoel H. Collier
Joel H. Collier
Significance: Current treatments for chronic inflammatory conditions rely on biologic drugs, commonly monoclonal antibodies that interfere with inflammatory signaling pathways. These drugs have made enormous contributions to the treatment of inflammatory diseases but still possess considerable drawbacks, including high cost that limits access in low-resource settings, the requirement for regularly repeated injections, and uneven efficacy. As an alternative to such biologics, active immunotherapies, in which an individual is induced to generate their own therapeutic antibodies, offer considerable potential advantages. Here, we report chemically defined nanomaterials inducing therapeutic responses in two models of inflammation in mice. The materials were produced by coassembling defined T cell epitopes, B cell epitopes, and an engineered fragment of complement protein C3dg into defined nanomaterials.

20 November 2025 in Acta Biomaterialia
Verified
Journal Article
Closed access
EREmily F Roe
Emily F Roe
NVNicole L Votaw
Nicole L Votaw
KLKat M Lazar
Kat M Lazar
KBKaitlyn N Burke
Kaitlyn N Burke
HMHector A Miranda
Hector A Miranda
JCJoel H Collier
Joel H Collier